DURGA-2
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma
What will happen during the trial?
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 40 patients (estimated)
- Sponsors
- AstraZeneca
- Tags
- CAR T Cell, CD19, B-Cell Maturation Antigen (BCMA), Monotherapy, Single Cohort, High Risk, Open Label
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2146
- NCT Identifier
- NCT07073547
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.